LAURA ANDWOOD: Open Payments
NPI 1841956083 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 10 payments from 6 companies in 2025. Trend: 2023 $117 · 2024 $354 · 2025 $621
Food & beverage: $423Education: $198
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 3 | $322 |
| Abbott Laboratories | 2 | $164 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $38 |
| United Therapeutics Corporation | 1 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
Products named: OPSUMIT, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, UPTRAVI, AMVUTTRA, Remodulin, Kerendia, CAMZYOS, ELIQUIS.
Industry payments across NY — which companies pay providers there.
